Sanofi (EPA: SASY) has announced encouraging late-stage clinical trial results for its investigational drug amlitelimab, ...

Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase studies.

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

After eight weeks, 75% of participants treated with the Corvus pill, called soquelitinib, achieved at least a 75% improvement ...

Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

No one should have to suffer from the dry, flaky skin and blisters that are the most common symptoms of eczema, researchers at the Johns Hopkins School of Medicine want Marylanders to know. “Eczema is ...

The cold, dry air of winter brings challenges for those with chronic hand eczema. Chronic hand eczema (CHE), defined as hand ...

Millions of Brits with eczema are almost twice as likely to suffer agonising eye and bowel conditions, research suggests.

Outlook Eczema is a fairly common skin condition in young children, but the specific causes and triggers for your baby may be difficult to figure out. Work with your pediatrician to develop the best ...

"I always felt like there was just something wrong with me," Michelle Smith told Newsweek, after years of itchy skin.